A Phase 1B/2A Trial Of CEND-1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers (CENDIFOX)
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Cerepetide (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CENDIFOX
- 13 Jun 2024 According to a Lisata Therapeutics media release, the trial is funded by the KU Cancer Center and Lisata is supplying certepetide.
- 13 Jun 2024 According to a Lisata Therapeutics media release, the company look forward to both the completion of enrollment in the remaining two cohorts and the reporting of results.
- 13 Jun 2024 According to a Lisata Therapeutics media release, the company announced the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial.